These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33524184)

  • 1. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
    J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
    ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparison of follow-up treatment regimens for colorectal cancer liver metastases without objective response to neoadjuvant chemotherapy: direct surgery or surgery after second-line chemotherapy].
    Lyu XY; Bi XY; Zhao H; Chen QC; Luo ZW; Zhang BL; Zhang XS; Cai JQ
    Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):454-460. PubMed ID: 35359087
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of margin status and neoadjuvant chemotherapy on survival, recurrence after liver resection for colorectal liver metastasis.
    Pandanaboyana S; White A; Pathak S; Hidalgo EL; Toogood G; Lodge JP; Prasad KR
    Ann Surg Oncol; 2015 Jan; 22(1):173-9. PubMed ID: 25084766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
    Vogl TJ; Lahrsow M; Albrecht MH; Hammerstingl R; Thompson ZM; Gruber-Rouh T
    Eur J Radiol; 2018 May; 102():138-145. PubMed ID: 29685527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.
    Khoo E; O'Neill S; Brown E; Wigmore SJ; Harrison EM
    HPB (Oxford); 2016 Jun; 18(6):485-93. PubMed ID: 27317952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative FDG-PET-scan in patients with resectable colorectal liver metastases does not improve overall survival: a retrospective analyses stratified by clinical risk score.
    Ayez N; de Ridder J; Wiering B; Oyen WJ; de Wilt JH; Verhoef C
    Dig Surg; 2013; 30(4-6):451-8. PubMed ID: 24458160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis.
    Liu W; Zhou JG; Sun Y; Zhang L; Xing BC
    Oncotarget; 2016 Jun; 7(24):37277-37287. PubMed ID: 27074564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases.
    Buisman FE; van der Stok EP; Galjart B; Vermeulen PB; Balachandran VP; Coebergh van den Braak RRJ; Creasy JM; Höppener DJ; Jarnagin WR; Kingham TP; Nierop PMH; Sadot E; Shia J; Groot Koerkamp B; Grünhagen DJ; D'Angelica M; Verhoef C
    Clin Exp Metastasis; 2020 Oct; 37(5):593-605. PubMed ID: 32691187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
    Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
    Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy for resectable colorectal liver metastases: where now?
    Jones RP; Malik HZ; Fenwick SW; Poston GJ
    Eur J Surg Oncol; 2013 Aug; 39(8):807-11. PubMed ID: 23726258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence.
    Nakamura M; Hashimoto N; Mayahara H; Uezono H; Harada A; Nishikawa R; Matsuo Y; Kawaguchi H; Nishimura H
    Radiat Oncol; 2018 Apr; 13(1):75. PubMed ID: 29688858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
    Chen Q; Mao R; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
    Cancer Med; 2020 Nov; 9(21):7849-7862. PubMed ID: 32886456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer.
    Araujo R; Gonen M; Allen P; Blumgart L; DeMatteo R; Fong Y; Kemeny N; Jarnagin W; D'Angelica M
    Ann Surg Oncol; 2013 Dec; 20(13):4312-21. PubMed ID: 23897009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.